Study provides a more complete and complex picture of infectious disease ecology than before

"Only a fraction of drugs that show promise in animals end up proving safe and effective in humans," lead researcher says

The most significant equipment-related trend in bioprocessing over the past 15 years has been the replacement of reusable glass and steel equipment by single-use plastics.

New software programs should help identify potential avenues for improved drug treatments for diabetes and other diseases

Sanofi, a global health care company, recently signed an agreement with the University of Texas System to fund selected research programs focused on the early stages of drug discovery.

Most drug discovery efforts begin with a biological target—the molecule inside the body whose activity the drug is expected to enhance or diminish. Assurance that the target is pharmacologically accessible and responsible in some way for the disease in question is based on target validation studies.

The Salk Institute and Sanford Burnham Prebys Medical Discovery Institute created a compound that stops a cellular recycling process.

Meet Doug Frantz. The Max and Minnie Tomerlin Voelcker Distinguished Professor in Chemistry was selected by the pharmaceutical company Eli Lilly & Co. to receive its Outstanding Open Innovation Drug Discovery Collaborator Award.

For decades, scientists have known that ET-743, a compound extracted from a marine invertebrate called a mangrove tunicate, can kill cancer cells. The drug has been approved for use in patients in Europe and is in clinical trials in the U.S.

Antibodies are specific molecules that can lock onto a particular cellular structure to start, stop or otherwise temper a biological process. Because they are so specific, antibodies are at the forefront of drug discovery. So drug companies want a faster route to step one: identifying which of the millions of possible antibodies will work against molecules that cause disease.